2023
Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API)
Barbosa A, Chebabo A, Starling C, Pérez C, Cunha C, de Luna D, Nunes E, Zambrano G, Ferreira J, Croda J, Falavigna M, Gomes-da-Silva M, Thormann M, Cimerman S, Parahiba S, Tanni S, Bernardo W, Rodriguez-Morales A. Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API). Annals Of Clinical Microbiology And Antimicrobials 2023, 22: 67. PMID: 37550690, PMCID: PMC10408214, DOI: 10.1186/s12941-023-00623-w.Peer-Reviewed Original ResearchConceptsUse of hydroxychloroquineInfectious diseasesCOVID-19Treatment of outpatientsSARS-CoV-2/COVIDSevere COVID-19Evidence-based guidelinesPan American AssociationGuideline development processLack of benefitEvidence-based medicineAdverse eventsMechanical ventilationClinical manifestationsTherapeutic optionsPharmacological treatmentCOVID-19 episodeInpatient settingAmerican guidelinesGRADE systemSystematic reviewStrong recommendationsProphylaxisOutpatientsDisease
2019
Origanum vulgare L. essential oil inhibits the growth of carbapenem-resistant gram-negative bacteria
Vasconcelos N, Croda J, Silva K, Motta M, Maciel W, Limiere L, Simionatto S. Origanum vulgare L. essential oil inhibits the growth of carbapenem-resistant gram-negative bacteria. Revista Da Sociedade Brasileira De Medicina Tropical 2019, 52: e20180502. PMID: 31271619, DOI: 10.1590/0037-8682-0502-2018.Peer-Reviewed Original ResearchConceptsCarbapenem-resistant strainsAlternative therapeutic optionTime-kill assaysMultidrug-resistant bacteriaTherapeutic optionsMinimum inhibitory concentrationAcinetobacter baumanniiCell countCarbapenemase productionKill assaysOriganum vulgare L. essential oilL. essential oilKlebsiella pneumoniaeInhibitory concentrationDrug developmentResistant bacteriaH treatmentSerratia marcescensAntimicrobial effectNegative bacteria
2018
A high mortality rate associated with multidrug-resistant Acinetobacter baumannii ST79 and ST25 carrying OXA-23 in a Brazilian intensive care unit
da Silva K, Maciel W, Croda J, Cayô R, Ramos A, de Sales R, Kurihara M, Vasconcelos N, Gales A, Simionatto S. A high mortality rate associated with multidrug-resistant Acinetobacter baumannii ST79 and ST25 carrying OXA-23 in a Brazilian intensive care unit. PLOS ONE 2018, 13: e0209367. PMID: 30592758, PMCID: PMC6310363, DOI: 10.1371/journal.pone.0209367.Peer-Reviewed Original ResearchMeSH KeywordsAcinetobacter baumanniiAcinetobacter InfectionsAdultAgedAged, 80 and overAnti-Bacterial AgentsBacterial ProteinsBeta-LactamasesBrazilCase-Control StudiesCross InfectionDrug Resistance, Multiple, BacterialFemaleHospital MortalityHumansIntensive Care UnitsMaleMicrobial Sensitivity TestsMiddle AgedConceptsOXA-23-producing A. baumanniiHigh mortality rateA. baumanniiMortality rateRisk factorsHealthcare-related risk factorsBrazilian intensive care unitsIntensive care unit patientsIntensive care unit settingCarbapenem-resistant Acinetobacter baumanniiISAba1 insertion sequenceA. baumannii infectionsCare unit patientsIntensive care unitBlaOXA-51 geneUse of cephalosporinsCase-control studyBaumannii infectionsUnit patientsCare unitNasogastric tubeTherapeutic optionsUnit settingNosocomial infectionsSuch infections